Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 9/2005

01.09.2005 | Review Article

Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies

verfasst von: Petra Feyer, M. Heinrich Seegenschmiedt, Maria Steingraeber

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2005

Einloggen, um Zugang zu erhalten

Abstract

Radiotherapy-induced nausea and vomiting (RINV) can be one of the most distressing symptoms of radiotherapy treatment, which if incompletely controlled may last for several weeks with fractionated radiotherapy and prevent completion of the planned treatment course. Current treatment guidelines recommend the use of 5-HT3 receptor antagonists with or without corticosteroids for highly and moderately emetogenic radiotherapy, though only granisetron and ondansetron are currently indicated for RINV in most countries. Granisetron is a potent and highly selective 5-HT3 receptor antagonist, with demonstrated efficacy in RINV in both placebo-controlled and comparative studies. In this paper the clinical experience with granisetron in RINV is reviewed, and its efficacy and safety compared with other antiemetic therapies.
Literatur
1.
Aapro M, Bourke JP (2003) Rapid intravenous administration of granisetron prior to chemotherapy is not arrhythmogenic: results of a pilot study. Eur J Cancer 39:927–931PubMed
2.
Aass N, Hatun DE, Thoresen M, Fossa SD (1997) Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients. Radiother Oncol 45:125–128PubMed
3.
Abbott B, Ippoliti C, Bruton J, Neumann J, Whaley R, Champlin R (1999) Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. Bone Marrow Transplant 23:265–269PubMed
4.
Abbott B, Ippoliti C, Hecth D, Bruton J, Whaley B, Champlin R (2000) Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation. Bone Marrow Transplant 25:1279–1283PubMed
5.
Belkacemi Y, Ozsahin M, Pene F, et al (1996) Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis. Int J Radiat Oncol Biol Phys 36:77–82PubMed
6.
Bey P, Wilkinson PM, Resbeut M, et al (1996) A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer 4:378–383PubMed
7.
Bloomer JC, Baldwin SJ, Smith GJ, et al (1994) Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 38:557–566PubMed
8.
Blower PR (1995) A pharmacologic profile of oral granisetron (Kytril tablets). Semin Oncol 22 [Suppl 10]:3–5
9.
Blower PR (2002) 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J 8:405–414PubMed
10.
Blower P (2003) Granisetron: relating pharmacology to clinical efficacy. Support Care Cancer 11:93–100PubMed
11.
Cowan JD, Neidhart J, McClure S, et al (1991) Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst 83:1077–1084PubMed
12.
Davis MP, Homsi J (2001) The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer 9:442–451PubMed
13.
Dixon CM, Colthup PV, Serabjit-Singh CJ, et al (1995) Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 23:1225–1230PubMed
14.
Extermann M (2000) Assessment of the older cancer patient. Hematol Oncol Clin North Am 14:63–77PubMed
15.
Fauser AA, Russ W, Bischoff M (1997) Oral dolasetron mesilate (MDL 73,147EF) for the control of emesis during fractionated total-body irradiation and high-dose cyclophosphamide in patients undergoing allogeneic bone marrow transplantation. Support Care Cancer 5:219–222PubMed
16.
Feyer PC, Stewart AL, Titlbach OJ (1998) Aetiology and prevention of emesis induced by radiotherapy. Support Cancer Care 6:253–260
17.
Freeman AJ, Cunningham KT, Tyers MB (1992) Selectivity of 5-HT3 receptor antagonists and anti-emetic mechanisms of action. Anticancer Drugs 3:79–85PubMed
18.
Franzen L, Nyman J, Hagberg H, et al (1996) A randomized placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol 7:587–592PubMed
19.
Gregory RE, Ettinger DS (1998) 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 55:173–189PubMed
20.
Goldberg RM, Mabee J, Chan L, Wong S (1996) Drug–drug interactions in the elderly: analysis of a high risk population. Am J Emerg Med 14:447–450PubMed
21.
Goshman L, Fish J, Roller K (1999) Clinically significant cytochrome P450 drug interactions. J Pharm Soc Wis 23–38
22.
The Italian Group for Antiemetic Research in Radiotherapy (1999) Radiation-induced emesis: a prospective observational multicenter Italian trial. Int J Radiat Oncol Biol Phys 44:619–625
23.
Kaiser R, Sezer O, Papies A, et al (2002) Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805–2811PubMed
24.
Kenney WL, Chiu P (2001) Influence of age on thirst and fluid intake. Med Sci Sports Exerc 33:1524–1532PubMed
25.
Krengli M, Lazzari R, Manara M (1996) Use of orally administered granisetron in radiotherapy-induced emesis (in Italian). Minerva Med 87:605–608PubMed
26.
Lanciano R, Sherman DM, Michalski J, Preston AJ, Yocom K, Friedman C (2001) The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy. Cancer Invest 19:763–772PubMed
27.
LeBourgeois JP, McKenna CJ, Coster B, et al (1999) Efficacy of ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT3 receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Clin Oncol 11:340–347
28.
Lindley C, Blower P (2000) Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis. Am J Health Syst Pharm 57:1685–1697PubMed
29.
Logue JP, Magee B, Hunter RD, Murdoch RD (1991) The antiemetic effect of granisetron in lower hemibody radiotherapy. Clin Oncol 3:247–249
30.
MASCC Consensus conference on antiemetic therapy, Perugia, 29–31 March 2004. Available at www.​mascc.​org. Accessed July 2004
31.
Maisano R, Pergolizzi S, Settineri N (1998) Escalating dose of oral ondansetron in the prevention of radiation induced emesis. Anticancer Res 18:2011–2013PubMed
32.
Miralbell R, Coucke P Behrouz F, et al (1995) Nausea and vomiting in fractionated radiotherapy: a prospective on-demand trial of tropisetron rescue for non-responders to metoclopramide. Eur J Cancer 31A:1461–1464PubMed
33.
Okamoto S, Takahashi S, Tanosaki R, et al (1996) Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomised study. Bone Marrow Transplant 17:679–683PubMed
34.
Orchard PJ, Rogosheske J, Burns L, et al (1999) A prospective randomised trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation. Biol Blood Marrow Transplant 5:386–393PubMed
35.
Palmer R (1994) Efficacy and safety of granisetron (Kytril) in two special patient populations: children and adults with impaired hepatic function. Semin Oncol 21 [Suppl 5]:22–25PubMed
36.
Perez EA, Hesketh P, Sandbach J, et al (1998) Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16:754–760PubMed
37.
Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C (1998) Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am 4:52–58PubMed
38.
Prentice HG, Cunningham S, Gandhi L, Cunningham J, Collis C, Hamon MD (1995) Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant 15:445–448PubMed
39.
Priestman TJ, Roberts JT, Upadhyaya BK (1993) A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin Oncol (R Coll Radiol) 5:358–363
40.
Priestman TJ, Roberts JT, Lucraft H, Collis CH, Adams M, Upadhyaya BK, Priestman S (1990) Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol (R Coll Radiol) 2:71–75
41.
Rapoport AP, Meisenberg B, Sarkodee-Adoo C, et al (2002) Autotransplantation for advanced lymphoma and Hodgkin’s disease by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 29:303–312PubMed
42.
Reske SN, Bunjes D, Bucmann I, et al (2001) Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation. Eur J Nucl Med 28:807–815PubMed
43.
Roberts JT, Priestman TJ (1993) A review of ondansetron in the management of radiotherapy-induced emesis. Oncology 50:173–179PubMed
44.
Roila F, Ciccarese G, Palladino MA, De Angelis V (1998 ) Prevention of radiotherapy-induced emesis. Tumori 84:274–278PubMed
45.
Rutqvist LE, Lax I, Fornander T, Johansson H (1992) Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys 22:1157–1158PubMed
46.
Sanwald P, David M, Dow J (1996) Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos 14:602–609
47.
Scarantino CW, Ornitz RO, Hoffman LG, Anderson RF (1994) On the mechanism of radiation-induced emesis: the role of serotonin. Int J Radiat Oncol Biol Phys 30:825–830PubMed
48.
Schwella N, Konig V, Schwerdtfeger R, et al (1994) Ondansetron for efficient emesis control during total body irradiation. Bone Marrow Transplant 13:169–171PubMed
49.
Seegenschmiedt MH (2001) Qualitätsmanagement in der radiookolgie. Onkologe 6:291–306
50.
Spitzer TR, Bryson JC, Cirenza E, et al (1994) Randomised double-blind placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. J Clin Oncol 12:2432–2438PubMed
51.
Spitzer TR, Friedman CJ, Bushnell W, Frankel SR, Raschko J (2000) Double-blind randomised, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant 26:203–210PubMed
52.
Sykes AJ, Kiltie AE, Stewart AL (1997) Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. Support Care Cancer 5:500–503PubMed
53.
Van Wijngaarden I, Tulp MT, Soudijn W (1990) The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 138:301–302
54.
Yancik R, Ries LAG (2000) Aging and cancer in America. Hematol Oncol Clin North Am 14:17–23PubMed
Metadaten
Titel
Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies
verfasst von
Petra Feyer
M. Heinrich Seegenschmiedt
Maria Steingraeber
Publikationsdatum
01.09.2005
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2005
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-004-0766-3

Weitere Artikel der Ausgabe 9/2005

Supportive Care in Cancer 9/2005 Zur Ausgabe

Original Article

Another form to fill in! Clients’ reflections on the hospice use of questionnaires

Original Article

The cancer pain experience of Israeli adults 65 years and older: the influence of pain interference, symptom severity, and knowledge and attitudes on pain and pain control

Short Communication

Development of a prognostic index in cancer patients with low performance status

Editorial

CAM for cancer?

Original Article

The problems experienced by patients with cancer and their needs for palliative care

Original Article

An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise